HeimATYR • NASDAQ
add
aTyr Pharma Inc
3,03 $
Eftir lokun(1,98%)+0,060
3,09 $
Lokað: 22. nóv., 17:03:35 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
2,98 $
Dagbil
2,95 $ - 3,19 $
Árabil
1,42 $ - 3,19 $
Markaðsvirði
254,35 m. USD
Meðalmagn
1,28 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | — | — |
Rekstrarkostnaður | 3,34 m. | 25,93% |
Nettótekjur | -17,26 m. | -52,20% |
Hagnaðarhlutfall | — | — |
Hagnaður á hvern hlut | -0,23 | -15,00% |
EBITDA | -17,96 m. | -44,42% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 65,99 m. | -35,39% |
Heildareignir | 91,62 m. | -26,75% |
Heildarskuldir | 26,48 m. | -1,45% |
Eigið fé alls | 65,14 m. | — |
Útistandandi hlutabréf | 83,94 m. | — |
Eiginfjárgengi | 3,47 | — |
Arðsemi eigna | -45,92% | — |
Ávöxtun eigin fjár | -52,14% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -17,26 m. | -52,20% |
Handbært fé frá rekstri | -13,16 m. | -37,65% |
Reiðufé frá fjárfestingum | 17,95 m. | 309,45% |
Reiðufé frá fjármögnun | -105,00 þ. | -103,91% |
Breyting á handbæru fé | 4,68 m. | 287,77% |
Frjálst peningaflæði | -6,49 m. | -12,66% |
Um
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Stofnsett
1. jan. 2005
Vefsvæði
Starfsfólk
58
